Evidence map›Paper›PMID 31555833›Full record

ReviewDer Anaesthesist2019

[Infections due to multidrug-resistant pathogens : Pathogens, resistance mechanisms and established treatment options].

D C Richter, T Brenner, A Brinkmann, B Grabein, M Hochreiter, A Heininger, D Störzinger, J Briegel, M Pletz, M A Weigand and 1 more

Erratum issuedOpen access · bronzeAbstract readReview
PubMed Publisher
In one paragraph

Review in Der Anaesthesist, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.1field-weighted citation impact, top 60% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 6 institutions in 1 country.

D C RichterKlinik für Anästhesiologie, Universitätsklinikum Heidelberg, Im Neuenheimer Feld 110, 69120, Heidelberg, Deutschland. daniel.richter@med.uni-heidelberg.de.
T BrennerKlinik für Anästhesiologie, Universitätsklinikum Heidelberg, Im Neuenheimer Feld 110, 69120, Heidelberg, Deutschland.
A BrinkmannKlinik für Anästhesie, operative Intensivmedizin und spezielle Schmerztherapie, Klinikum Heidenheim, Heidenheim, Deutschland.
B GrabeinStabsstelle "Klinische Mikrobiologie und Krankenhaushygiene", Klinikum der Universität München, München, Deutschland.
M HochreiterKlinik für Anästhesiologie, Universitätsklinikum Heidelberg, Im Neuenheimer Feld 110, 69120, Heidelberg, Deutschland.
A HeiningerZentrum für Infektiologie, Sektion für Krankenhaus- und Umwelthygiene, Universitätsklinikum Heidelberg, Heidelberg, Deutschland.
D StörzingerApotheke, Universitätsklinikum Heidelberg, Heidelberg, Deutschland.
J BriegelKlinik für Anästhesiologie, Ludwig-Maximilians-Universität, München, Deutschland.
M PletzInstitut für Infektionsmedizin und Krankenhaushygiene, Universitätsklinikum Jena, Jena, Deutschland.
M A WeigandKlinik für Anästhesiologie, Universitätsklinikum Heidelberg, Im Neuenheimer Feld 110, 69120, Heidelberg, Deutschland.
C LichtensternKlinik für Anästhesiologie, Universitätsklinikum Heidelberg, Im Neuenheimer Feld 110, 69120, Heidelberg, Deutschland.
Heidelberg University · DEUniversity Hospital Heidelberg · DEJena University Hospital · DELudwig-Maximilians-Universität München · DEMünchen Klinik · DESiloah St. Trudpert Klinikum · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The increase in resistant pathogens has long been a global problem. Complicated life-threatening infections due to multidrug-resistant pathogens (MRD) meanwhile occur regularly in intensive care medicine. An important and also potentially modifiable factor of the rapid spread of resistance is the irrational use of broad spectrum antibiotics in human medicine. In addition to many other resistance mechanisms, beta-lactamases play an important role in Gram-negative pathogens. They are not uncommonly the leading reason of difficult to treat infections and the failure of known routinely used broad spectrum antibiotics, such as cephalosporins, (acylamino)penicillins and carbapenems. Strategies for containment of MRDs primaríly target the rational use of antibiotics. In this respect interdisciplinary treatment teams, e.g. antibiotic stewardship (ABS) and infectious diseases stewardship (IDS) play a major role.

Indexed as

Anti-Bacterial AgentsCarbapenemsCephalosporinsDrug Resistance, BacterialHumansPenicillinsAnti-Bacterial AgentsCarbapenemsCephalosporinsPenicillinsBeta-lactamasesCarbapenem-resistant EnterobacteriaceaeMethicillin-resistant Staphylococcus aureusSepsisVancomycin-resistant Enterococci

Identifiers

PMID31555833
OpenAlexW2976126647

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.